Endocrine Disruption Screening - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB512243912

Publication Date:

December 3, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The Endocrine Disruptor Screening is used to screen pesticides, chemicals, and other environmental contaminants for their potential to impact the androgen, estrogen, and thyroid hormone systems.
The global market for Endocrine Disruption Screening was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The Endocrine Disruptor Screening is used to screen pesticides, chemicals, and other environmental contaminants for their potential to impact the androgen, estrogen, and thyroid hormone systems.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Endocrine Disruption Screening, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Endocrine Disruption Screening by region & country, by Type, and by Application.
The Endocrine Disruption Screening market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Endocrine Disruption Screening.
Market Segmentation
By Company
Creative Bioarray
Xenometrix AG
Charles River Laboratories
Eurofins Scientific
Smithers
SGS SA
JRF Global
M茅rieux NutriSciences
Alpha Analytical
Segment by Type:
In Vitro Screening
In Vivo Screening
Segment by Application
Agricultural
Medical
Environmental
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Endocrine Disruption Screening manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Endocrine Disruption Screening in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Endocrine Disruption Screening in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Market Overview
1.1 Endocrine Disruption Screening Product Introduction
1.2 Global Endocrine Disruption Screening Market Size Forecast
1.3 Endocrine Disruption Screening Market Trends & Drivers
1.3.1 Endocrine Disruption Screening Industry Trends
1.3.2 Endocrine Disruption Screening Market Drivers & Opportunity
1.3.3 Endocrine Disruption Screening Market Challenges
1.3.4 Endocrine Disruption Screening Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Endocrine Disruption Screening Players Revenue Ranking (2023)
2.2 Global Endocrine Disruption Screening Revenue by Company (2019-2024)
2.3 Key Companies Endocrine Disruption Screening Manufacturing Base Distribution and Headquarters
2.4 Key Companies Endocrine Disruption Screening Product Offered
2.5 Key Companies Time to Begin Mass Production of Endocrine Disruption Screening
2.6 Endocrine Disruption Screening Market Competitive Analysis
2.6.1 Endocrine Disruption Screening Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Endocrine Disruption Screening Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Endocrine Disruption Screening as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 In Vitro Screening
3.1.2 In Vivo Screening
3.2 Global Endocrine Disruption Screening Sales Value by Type
3.2.1 Global Endocrine Disruption Screening Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Endocrine Disruption Screening Sales Value, by Type (2019-2030)
3.2.3 Global Endocrine Disruption Screening Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Agricultural
4.1.2 Medical
4.1.3 Environmental
4.2 Global Endocrine Disruption Screening Sales Value by Application
4.2.1 Global Endocrine Disruption Screening Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Endocrine Disruption Screening Sales Value, by Application (2019-2030)
4.2.3 Global Endocrine Disruption Screening Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Endocrine Disruption Screening Sales Value by Region
5.1.1 Global Endocrine Disruption Screening Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Endocrine Disruption Screening Sales Value by Region (2019-2024)
5.1.3 Global Endocrine Disruption Screening Sales Value by Region (2025-2030)
5.1.4 Global Endocrine Disruption Screening Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Endocrine Disruption Screening Sales Value, 2019-2030
5.2.2 North America Endocrine Disruption Screening Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Endocrine Disruption Screening Sales Value, 2019-2030
5.3.2 Europe Endocrine Disruption Screening Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Endocrine Disruption Screening Sales Value, 2019-2030
5.4.2 Asia Pacific Endocrine Disruption Screening Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Endocrine Disruption Screening Sales Value, 2019-2030
5.5.2 South America Endocrine Disruption Screening Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Endocrine Disruption Screening Sales Value, 2019-2030
5.6.2 Middle East & Africa Endocrine Disruption Screening Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Endocrine Disruption Screening Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Endocrine Disruption Screening Sales Value
6.3 United States
6.3.1 United States Endocrine Disruption Screening Sales Value, 2019-2030
6.3.2 United States Endocrine Disruption Screening Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Endocrine Disruption Screening Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Endocrine Disruption Screening Sales Value, 2019-2030
6.4.2 Europe Endocrine Disruption Screening Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Endocrine Disruption Screening Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Endocrine Disruption Screening Sales Value, 2019-2030
6.5.2 China Endocrine Disruption Screening Sales Value by Type (%), 2023 VS 2030
6.5.3 China Endocrine Disruption Screening Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Endocrine Disruption Screening Sales Value, 2019-2030
6.6.2 Japan Endocrine Disruption Screening Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Endocrine Disruption Screening Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Endocrine Disruption Screening Sales Value, 2019-2030
6.7.2 South Korea Endocrine Disruption Screening Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Endocrine Disruption Screening Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Endocrine Disruption Screening Sales Value, 2019-2030
6.8.2 Southeast Asia Endocrine Disruption Screening Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Endocrine Disruption Screening Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Endocrine Disruption Screening Sales Value, 2019-2030
6.9.2 India Endocrine Disruption Screening Sales Value by Type (%), 2023 VS 2030
6.9.3 India Endocrine Disruption Screening Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Creative Bioarray
7.1.1 Creative Bioarray Profile
7.1.2 Creative Bioarray Main Business
7.1.3 Creative Bioarray Endocrine Disruption Screening Products, Services and Solutions
7.1.4 Creative Bioarray Endocrine Disruption Screening Revenue (US$ Million) & (2019-2024)
7.1.5 Creative Bioarray Recent Developments
7.2 Xenometrix AG
7.2.1 Xenometrix AG Profile
7.2.2 Xenometrix AG Main Business
7.2.3 Xenometrix AG Endocrine Disruption Screening Products, Services and Solutions
7.2.4 Xenometrix AG Endocrine Disruption Screening Revenue (US$ Million) & (2019-2024)
7.2.5 Xenometrix AG Recent Developments
7.3 Charles River Laboratories
7.3.1 Charles River Laboratories Profile
7.3.2 Charles River Laboratories Main Business
7.3.3 Charles River Laboratories Endocrine Disruption Screening Products, Services and Solutions
7.3.4 Charles River Laboratories Endocrine Disruption Screening Revenue (US$ Million) & (2019-2024)
7.3.5 Eurofins Scientific Recent Developments
7.4 Eurofins Scientific
7.4.1 Eurofins Scientific Profile
7.4.2 Eurofins Scientific Main Business
7.4.3 Eurofins Scientific Endocrine Disruption Screening Products, Services and Solutions
7.4.4 Eurofins Scientific Endocrine Disruption Screening Revenue (US$ Million) & (2019-2024)
7.4.5 Eurofins Scientific Recent Developments
7.5 Smithers
7.5.1 Smithers Profile
7.5.2 Smithers Main Business
7.5.3 Smithers Endocrine Disruption Screening Products, Services and Solutions
7.5.4 Smithers Endocrine Disruption Screening Revenue (US$ Million) & (2019-2024)
7.5.5 Smithers Recent Developments
7.6 SGS SA
7.6.1 SGS SA Profile
7.6.2 SGS SA Main Business
7.6.3 SGS SA Endocrine Disruption Screening Products, Services and Solutions
7.6.4 SGS SA Endocrine Disruption Screening Revenue (US$ Million) & (2019-2024)
7.6.5 SGS SA Recent Developments
7.7 JRF Global
7.7.1 JRF Global Profile
7.7.2 JRF Global Main Business
7.7.3 JRF Global Endocrine Disruption Screening Products, Services and Solutions
7.7.4 JRF Global Endocrine Disruption Screening Revenue (US$ Million) & (2019-2024)
7.7.5 JRF Global Recent Developments
7.8 M茅rieux NutriSciences
7.8.1 M茅rieux NutriSciences Profile
7.8.2 M茅rieux NutriSciences Main Business
7.8.3 M茅rieux NutriSciences Endocrine Disruption Screening Products, Services and Solutions
7.8.4 M茅rieux NutriSciences Endocrine Disruption Screening Revenue (US$ Million) & (2019-2024)
7.8.5 M茅rieux NutriSciences Recent Developments
7.9 Alpha Analytical
7.9.1 Alpha Analytical Profile
7.9.2 Alpha Analytical Main Business
7.9.3 Alpha Analytical Endocrine Disruption Screening Products, Services and Solutions
7.9.4 Alpha Analytical Endocrine Disruption Screening Revenue (US$ Million) & (2019-2024)
7.9.5 Alpha Analytical Recent Developments
8 Industry Chain Analysis
8.1 Endocrine Disruption Screening Industrial Chain
8.2 Endocrine Disruption Screening Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Endocrine Disruption Screening Sales Model
8.5.2 Sales Channel
8.5.3 Endocrine Disruption Screening Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Creative Bioarray
Xenometrix AG
Charles River Laboratories
Eurofins Scientific
Smithers
SGS SA
JRF Global
M茅rieux NutriSciences
Alpha Analytical

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂